Patients should not be switched to another medicinal product as anti-erythropoietin antibodies cross-react with other erythropoietins.
Patsienti ei tohi üle viia teisele ravimile, kuna erütropoetiini- vastased antikehad ristreageerivad teiste erütropoetiinidega.